Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer--Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

P.-L. Kellokumpu-Lehtinen, M. Hjälm-Eriksson, C. Thellenberg-Karlsson, L. Åström, L. Franzen, A.-S. Fransson, M.J. Leskinent, M. Zeke, T. Huttunen, C. Ginman

Research output: Contribution to journalArticleScientificpeer-review

6 Citations (Scopus)
Original languageEnglish
Pages (from-to)823-830
JournalEuropean Urology
Volume76
Issue number6
DOIs
Publication statusPublished - 2019
Publication typeA1 Journal article-refereed

Keywords

  • Adjuvant
  • Docetaxel
  • Prostate cancer
  • Radical radiotherapy
  • Randomised trial

Publication forum classification

  • Publication forum level 3

Cite this